# HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

> **NCT06770452** · PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 32 (estimated)

## Conditions studied

- Metastatic Pancreatic Carcinoma

## Interventions

- **DRUG:** HRS-4642
- **DRUG:** Nimotuzumab
- **DRUG:** gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT06770452
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2027-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770452, "HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06770452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*